Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis

被引：0
|
作者：
Strasser, S. I.
Gane, E. J.
Weilert, F.
Sievert, W.
George, J.
Crawford, D.
Ngu, M. C.
Heathcote, E. J.
Marcellin, P.
Sorbel, J.
Rousseau, F.
机构：
[1] Royal Prince Alfred Hosp, AW Morrow GE & Liver Ctr, Sydney, NSW, Australia
[2] Middlemore Hosp, Dept Gastroenterol, Manukau City, New Zealand
[3] Waikato Hosp, Hamilton, New Zealand
[4] Monash Med Ctr, Clayton, Vic, Australia
[5] Westmead Hosp, Storr Liver Unit, Univ Sydney, Westmead, NSW, Australia
[6] Princess Alexandra Hosp, Dept Gastroenterol & Hepatol, Woolloongabba, Qld, Australia
[7] Concord Repatriat Gen Hosp, Dept Gastroenterol, Concord, NSW, Australia
[8] Univ Toronto, Dept Gastroenterol, Toronto, ON M5S 1A1, Canada
[9] Univ Paris, Clichy, France
[10] Gilead Sci Inc, Durham, NC USA
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A309 / A309
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use
    Gane, E.
    Seto, W. K.
    Janssen, H.
    Caruntu, F. A.
    Kim, H. J.
    Abdurakhmanov, D.
    Nishiguchi, S.
    Andrzej, H.
    Bae, H.
    Mo, S.
    Suri, V.
    Gaggar, A.
    Flaherty, J. F.
    Kao, J-H
    Brunetto, M.
    Buti Ferret, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 42 - 43
  • [22] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
    Seto, Wai Kay Walter
    Buti, Maria
    Izumi, Namiki
    Lim, Young-Suk
    Kao, Jia-Horng
    Streinu-Cercel, Adrian
    Nurmukhametova, Elena
    Ma, Xiaoli
    Tabak, Fehmi
    Jablkowski, Maciej
    Suri, Vithika
    Flaherty, John F.
    Lau, Audrey H.
    Gaggar, Anuj
    Mo, Shuyuan
    Chowdhury, Abhijit
    Fung, Scott K.
    Chuang, Wan-Long
    Gane, Edward J.
    HEPATOLOGY, 2018, 68 : 240A - 241A
  • [23] Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load
    Baijun Li
    Zhaozhe Liu
    Xing Liu
    Dongchun Liu
    Mingyu Duan
    Ye Gu
    Qiong Liu
    Qiang Ma
    Yushi Wei
    Yan Wang
    Hepatology International, 2021, 15 : 1103 - 1108
  • [24] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) VS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN EAST ASIAN CHRONIC HEPATITIS B PATIENTS FOLLOWING 5-YEARS OF TREATMENT
    Wong, Grace Lai Hung
    Gane, Edward
    Pan, Calvin
    Lim, Young-Suk
    Fung, Scott
    Izumi, Namiki
    Ma, Mang
    Chan, Carol Yee Kwan
    Shalimar, Dr
    Buti, Maria
    GUT, 2021, 70 : A76 - A76
  • [25] Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load
    Li, Baijun
    Liu, Zhaozhe
    Liu, Xing
    Liu, Dongchun
    Duan, Mingyu
    Gu, Ye
    Liu, Qiong
    Ma, Qiang
    Wei, Yushi
    Wang, Yan
    HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1103 - 1108
  • [26] TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES
    Chan, Henry Lik-Yuen
    Seto, Wai Kay
    Fung, Scott
    Hou, Jinlin
    Pan, Calvin
    Chuang, Wan-Long
    Chang, Ting-Tsung
    Hui, Aric-Josun
    Chen, Chi-Yi
    Tsang, Tak Yin Owen
    Yang, Jenny
    Flaherty, John
    Gaggar, Anuj
    Mo, Shuyuan
    Kao, Jia-Horng
    GUT, 2018, 67 : A302 - A302
  • [27] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive chronic HBV (CHB): Week 48 efficacy and safety results
    Strasser, S.
    Roberts, S.
    Angus, P.
    Chan, H. L. Y.
    Fung, S.
    Seto, W. K.
    Chuang, W. L.
    Chen, C. Y.
    Kim, H. J.
    Hui, A. J.
    Janssen, H. L. A.
    Chowdhury, A.
    Tsang, T. Y. O.
    Mehta, R.
    Gane, E.
    Flaherty, J. F.
    Massetto, B.
    Kitrinos, K.
    Dinh, P.
    Subramanian, G. M.
    Mchutchison, J. G.
    Lim, Y. S.
    Acharya, S. K.
    Agarwal, K.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 82 - 82
  • [28] Tenofovir disoproxil fumarate (TDF) suppresses lamivudine-resistant HBV replication in patients co-infected with HIV/HBV
    Benhamou, Y
    Bochet, M
    Tubiana, R
    Thibault, V
    Suffisseau, L
    Sullivan, M
    Rooney, J
    Brosgart, C
    Bricaire, F
    Katlama, C
    Poynard, T
    JOURNAL OF HEPATOLOGY, 2002, 36 : 138 - 138
  • [29] Effects of tenofovir disoproxil fumarate (TDF) on renal function in chronic HBV patients in three global randomized studies
    Marcellin, P.
    Heathcote, E. J.
    Berg, T.
    Elsome, A. M.
    Anderson, J.
    Mondou, E.
    Coombs, D.
    Ebrahimi, R.
    Reddy, S.
    Lopatin, U.
    McNally, J.
    Ng, C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 103 - 103
  • [30] Tenofovir disoproxil fumarate (TDF) is highly active for treatment of chronic hepatitis B in subjects with cirrhosis
    Wang, Chia
    Buti, Maria
    Hadziyannis, Stephanos J.
    Mathurin, Philipe
    Sherman, Morris
    Strasser, Simone I.
    Petersen, Joerg
    Tong, Myron J.
    Sorbel, Jeff
    Mondou, Elsa
    Anderson, Jane
    Rousseau, Franck
    GASTROENTEROLOGY, 2008, 134 (04) : A808 - A809
12345